



GEDEON RICHTER

Health is our mission

Celebrating **125** years

**125** years

# THE RICHTER GROUP



# Specialty pharmaceutical company based in Hungary

Richter aims to be a **global innovator** contributing to the development of key scientific areas, while at the same time being committed to increasing the availability of medicines worldwide. Founded in **1901** and headquartered in Hungary, the Company operates the largest R&D centre in Central Europe, has a market capitalization of **EUR 5 billion** and a sales revenue of **EUR 2.3 billion** in 2025. Its research projects achieve major breakthroughs in innovative businesses such as neuropsychiatry and women's healthcare, while biotechnology and generic medicines strengthen the portfolio of affordable treatments. Committed to sustainable growth, Richter continuously invests in R&D, manufacturing excellence and digitalisation to drive innovation in the pharmaceutical industry.

For more information, please visit [www.gedeonrichter.com](http://www.gedeonrichter.com).



TRADITION

# Dynamic development

## Valuable expertise

One of the reasons of the Company's success is its wealth of experience and know-how accumulated over more than a century. Its founder, pharmacist Gedeon Richter obtained a licence to manufacture drugs in **1901**. He bought the "Sas" (Eagle) Pharmacy, which is still operating and still owned by the Company, and began to manufacture medicines in its laboratory. He later decided to manufacture drugs on an industrial scale and built a modern pharmaceutical factory in the Kőbánya district of Budapest in **1907**. The young pharmacist was always looking for and seizing new opportunities, and he put great emphasis on international relations and the quality of products. Success was founded on Richter's relentless dedication to research and innovation, which are still integral values of the Company. Thanks to its outstanding employees and managers, the Company was able to overcome great losses and weather the historical storms of the twentieth century. Richter has not only held on to its position in Hungary; it has greatly expanded its market participation all over the world. It is an important objective of Richter to further strengthen its global role and to continuously expand its product range. To this end, it is making large-scale investments and expanding its strategic partnerships in research and development, marketing and sales to ensure the dynamic development of the Richter Group in the future.

Richter is a Hungarian-based, innovation-driven, specialty pharmaceutical company. The Company's strategy is based on organic growth, aiming for targeted acquisitions, primarily in the field of gynaecology.

EUR 2.3 bn

in sales revenue



11,955

employees



Its mission is to preserve health and improve quality of life, for example by marketing original and biosimilar products with high added value and with specific know-how in their development and production.



2,800  
products



350  
formulations



150  
active substances



1,200  
experts in R&D



Regional  
leader  
in R&D




More than  
10%  
of sales revenue spent on  
R&D

# Vertically integrated operation

Research & Development  
Pharmaceutical manufacturing  
Wholesale and retail  
Marketing and Sales

---





**Top 2**  
in women's healthcare  
in EU



**Leader**  
in steroid production  
in the EU



Blue chip company  
listed on the  
**BSE**



**8+3**  
**original**  
products



**30%**  
of domestically financed  
R&D comes from Richter  
in Hungary



**Blockbuster**  
product in the US



Focus on  
**sustainability**  
in all activities



Unrivalled  
**biotechnology**  
capacities in Central and  
Eastern Europe



# Largest Hungarian pharmaceutical manufacturer

## Extensive international network

**93%** of the Company's pharmaceutical manufacturing revenue comes from its export activities: In 2024 it was **close to EUR 2 billion**. Our largest international markets: US, Russia, Poland, Germany and Spain.

50

direct presence in 50 countries

---

93%

of the sales revenue is  
generated abroad


---

50%


of the employees  
work abroad



## Breakdown of pharmaceutical sales by region



## Breakdown of pharmaceutical sales by Business Units





INNOVATION

# Original compounds

## Outstanding R&D activity

Research into original compounds has always been in the focus of Richter's strategy. Its R&D base with a staff of over **1,200 experts** is the most important pharmaceutical research centre in Central Eastern Europe. Besides its traditional expertise in central nervous system research, with recent acquisitions Gedeon Richter can gain a foothold in original research in WHC as well. Richter is also involved in generic drug development and biotechnology. The company spends the most on R&D in the region: over **10%** of its sales revenue, **EUR 229,3 million** in 2025.

The launch of Richter's antipsychotic on the US market in 2016 was a unique success for the Hungarian pharmaceutical industry, with the original product now available in several regions of the world. The high intellectual added value of the product was recognised with the Innovation Grand Prize and the Drug of the Year award in Hungary.



# GYNAECOLOGY

# Several decades of experience

## Comprehensive product range

We are targeting **women's health** on a global scale, where we aim to play a leading role in the areas of uterine fibroids/endometriosis, contraception, vaginal infections, menopause and we are planning to introduce new therapies for the urinary tract, PCOS and women's oncology. Building on its fully integrated value chain, its recently established original research and its ability to adopt external innovations, Richter will further expand its geographic focus by increasing its **presence in the United States** and strengthening its **position in Western Europe.**





# NEUROPSYCHIATRY

# World-class research

## Developing original R&D projects

Richter will focus on maximising the value of Cariprazine during the patent protection period, while ensuring that CNS remains a **value adding business** for the next decade. Existing **unmet needs**, the significant societal costs of mental disorders, the growing demand for treatments (including increasing awareness of mental diseases) and **promising innovations** continue to make original neuropsychiatric research attractive. Leveraging its unparalleled research and preclinical capabilities, its partnership with AbbVie and its well-established local ecosystem, Richter seeks to build **a powerful project portfolio** and develop a new molecule with blockbuster potential.



# BIOTECHNOLOGY



# High added value

## Strategic direction

Biosimilars represent the **fastest-growing** pharmaceutical sub-segment, driven by the patent expiry of biologics. Expected product launches and expanded CDMO (contract development and manufacturing) capacity make Biotechnology Richter's fastest growing business. The focus of key therapeutic areas includes promising markets in **immunology and musculoskeletal therapy**. Richter's goal is to continue to grow by launching additional **proprietary and licensed products**, so the company can develop as a strong, reliable biosimilar player. In addition to marketing our own biosimilar products, we also carry out contract development and manufacturing (CDMO) services for third parties.



# GENERAL MEDICINES



# Leading supplier of generics

## Outstanding retail portfolio

Over the past 70 years, Gedeon Richter has expanded its portfolio with a **wide range** of generic medicines, becoming a leader in this field in Central and Eastern Europe and the CIS. Its General Medicines portfolio provides broad access to **high-quality and affordable drugs**, including traditional Richter medicines, generic and licensed innovative products, and covers mainly cardiac and metabolic diseases, as well as central nervous system and rheumatology therapeutic areas. Our over-the-counter (OTC) product range plays an important role in selected countries, primarily in the cough, cold and pain relief segments.





CSR

# Health and quality of life

## Science education

The social environment in which the company operates has always been especially important for Richter. In line with its mission to improve **health** and **quality of life**, Richter supports and offers a wide range of health, scientific and educational initiatives. It helps to develop science education through grants and foundations, supporting both talented students and teachers who promote their subjects effectively. It provides considerable financial aid to healthcare institutions and patient organizations and plays a prominent role in safeguarding people's health. Richter's Health City, launched in 2009, is a unique initiative to provide the public with a free, all-day screening programme in the spirit of prevention. In addition, the Company pays special attention to the situation of Hungarian women. That is why the **Richter for Women** programme was created to advance women's social esteem and physical and mental well-being.

In 2024, as part of Richter's international CSR programme in Mali (Bamako), we financed the construction of a multifunctional women's health centre, the **"Gedeon Richter - House of Hope"**, which opened in early 2025.



RICHTER GROUP

### Subsidiaries and joint ventures in production

India, Vapi – Richter Themis Medicare (India) Private Ltd.  
 Poland, Grodzisk – Gedeon Richter Polska Sp. z o.o.  
 Germany, Bovenau – Richter BioLogics GmbH  
 Russia, Yegoryevsk – AO Gedeon Richter RUS  
 Romania, Târgu Mures – Gedeon Richter Romania S.A.

### Subsidiaries for WHC R&D

Belgium, Liège – Estetra SRL  
 Belgium, Liège – Hirundo Biosciences SA

### Representative offices

Armenia, Yerevan  
 Azerbaijan, Baku  
 Belarus, Minsk  
 Estonia, Tallinn  
 Georgia, Tbilisi  
 Kyrgyzstan, Bishkek  
 Latvia, Marupe  
 Lithuania, Vilnius  
 Moldova, Chisinau  
 Mongolia, Ulan Bator  
 Serbia, Belgrade  
 Tajikistan, Dushanbe  
 Turkmenistan, Ashgabat  
 Uzbekistan, Tashkent

### Commercial and marketing companies

Australia, Belrose – Gedeon Richter Australia PTY Ltd.  
 Austria, Vienna – Gedeon Richter Austria GmbH  
 Belgium, Groot-Bijgaarden – Gedeon Richter Benelux  
 Brasil, Sao Paulo – Gedeon Richter Do Brasil Importadora,  
 Exportadora E Distribuidora S.A.  
 Bulgaria, Sofia – Gedeon Richter Bulgaria Ltd.  
 Chile, Santiago – Gedeon Richter (Chile) SpA  
 China, Shanghai – SHE Healthcare (Shanghai) Company  
 Ltd., Gedeon Richter Pharmaceutical (China) Co. Ltd.  
 Columbia, Bogotá – Gedeon Richter Colombia S.A.S.

Croatia, Zagreb – Gedeon Richter Croatia d.o.o.  
 Curacao – Mediplus N. V.  
 Czech Republic, Prague – Gedeon Richter Marketing ČR  
 s.r.o.  
 Dominican Republic, Santo Domingo – Farmage  
 Dominicana S.R.L.  
 Ecuador, Quito – Gedeon Richter Ecuador SA  
 France, Paris – Gedeon Richter France S.A.S.  
 Germany, Cologne – Gedeon Richter Pharma GmbH  
 Hong-Kong – GRMed Company Ltd. (Hongkong), SHE  
 Healthcare Company Ltd.  
 Ireland, Dublin – Gedeon Richter Ireland Limited  
 Italy, Milan – Gedeon Richter Italia s.r.l.  
 Jamaica, Kingston – Medimpex West Indies/Jamaica Ltd.  
 Kazakhstan, Almaty – Gedeon Richter KZ LLP  
 Mexico, Tlalnepantla – Gedeon Richter Mexico, S.A.P.I. de  
 C.V.  
 Peru, Lima – Gedeon Richter Peru S.A.C.  
 Portugal, Lisbon – Gedeon Richter Portugal  
 Russia, Moscow – Gedeon Richter Farma O.O.O  
 Slovakia, Bratislava – Gedeon Richter Slovakia, s.r.o.  
 Slovenia, Ljubljana – Gedeon Richter d.o.o.  
 Spain, Barcelona – Gedeon Richter Ibérica S.A.  
 Switzerland, Geneva – Gedeon Richter (Schweiz) AG  
 Sweden, Stockholm – Gedeon Richter Nordics AB  
 Ukraine, Kiev – OOO Gedeon Richter Ukraine  
 United Kingdom, London – Gedeon Richter UK Ltd., Medim-  
 pex UK Ltd.  
 USA, Ridgewood – Gedeon Richter USA Inc.  
 Vietnam, Ho Chi Minh City – Gedeon Richter Vietnam Ltd.



GEDEON RICHTER



1103 Budapest, Gyömrői út 19–21.  
Telephone: +36 1 431 4000  
[www.gedeonrichter.com](http://www.gedeonrichter.com)  
2026.03.18. PR/317/2026